Farley did not elaborate on his views, but he is hardly the only Fortune 500 CEO who believes AI could spell trouble for ...

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

"The severity of this past flu season underscores the need for more effective vaccines," Moderna Chief Executive Stephane Bancel said. "An mRNA-based flu vaccine has the potential advantage to more ...

Moderna stock veered higher Monday after its flu shot proved to be as effective as older technology in a final-phase study.

Trump and Musk reignite feud over tax bill, stocks end first half at records, Moderna flu vaccine achieves promising results, ...

The Newspaper for Every Jewish Home.Moderna may have the edge over its competitors because of its reported advantage in the storage it requires.